11/23/2020 5:17 AM
Clarín.com
Society
Updated 11/23/2020 5:21 AM
The vaccine developed by the English University of Oxford and the pharmaceutical AstraZeneca against the coronavirus --in whose manufacture Argentina will participate-- showed
70.4% effectiveness
in preliminary studies, according to the joint announcement made this Monday by both institutions .
The data
contrasts
with the 95% effectiveness shown by the preparations produced by the companies Pfizer and Moderna, although the British antidote is cheaper and easier to keep.
"The efficacy and safety of this vaccine confirm that it will be very effective against Covid-19 and that it will have an immediate impact on this public health emergency," AstraZeneca chief executive Pascal Soriot said in a statement.
Today marks an important milestone in the fight against # COVID19.
Interim data show the #OxfordVaccine is 70.4% effective, & tests on two dose regimens show that it could be 90%, moving us one step closer to supplying it at low cost around the world >> https://t.co/fnHnKSqftT pic.twitter.com/2KYXPxFNz1
- University of Oxford (@UniofOxford) November 23, 2020
The researchers noted that their preparation "is effective in preventing many people from getting sick and has been shown to work well in different age groups."
From Oxford they detailed that two vaccine application regimens were carried out.
In those who received two normal doses, the vaccine was 62% effective.
In contrast, that record
rose to 90%
in cases where a lower dose was applied in the first instance and a full dose in the second instance.
Test leader Andrew Pollard highlighted the result of the second application regimen, noting that by using a smaller amount of the preparation, the vaccine could reach more people.
The goal is to apply
3 billion doses
in 2021.
Testing of the Oxford and AstraZeneca coronavirus vaccine is expected to reach 60,000 people by the end of the year.
AP Photo
In the statement, the temperature at which the vaccine can be stored was described as "crucial", at values between 2 and 8 degrees.
In this way,
existing infrastructure and logistics
in health systems
could be
used
, unlike Pfizer's (below -70 degrees).
The database with the results will be published "as soon as possible" to meet the independent evaluation criteria of the scientific environment.
"The next step is to work with regulatory bodies around the world to facilitate a new tool against Covid-19," says a video shared on social media from the University of Oxford.
Until the end of the year, tests will be carried out in the United States, Japan, Kenya and India, with the aim of
reaching 60 thousand participants
in the vaccine
trials
.
The Oxford and AstraZeneca vaccine is the one that Argentina will manufacture together with Mexico.
President Alberto Fernández expects him to arrive in the country next March.
Look also
How is the "vaccination plan" against the coronavirus organized by the Argentine government
The United States already has a date to start applying the coronavirus vaccine
